Side-by-side · Research reference

AHK-CuvsCJC-1295 (no DAC)

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED14/43 cited

BPhase 1HUMAN-REVIEWED15/51 cited

AHK-Cu

Tripeptide-Copper Complex · Cosmetic

10⁻¹² – 10⁻⁹ MActive range (in vitro)Pyo 2007

Dermal papilla cellsPrimary targetPyo 2007

TopicalRoute

Topical · Scalp / Skin

CJC-1295 (no DAC)

Short-acting GHRH · No DAC variant

100 mcgPer doseTeichman 2006

~30 minHalf-lifeIonescu 2006

Phase 1Evidence levelTeichman 2006 Sigalos 2018

SQ · Pre-sleep · 1–2×/day

01Mechanism of Action

Parameter

AHK-Cu

CJC-1295 (no DAC)

Primary target

Dermal papilla cells (DPCs) — specialized fibroblasts in hair follicle morphogenesisPyo 2007

Pituitary GHRH receptorTeichman 2006

Pathway

AHK-Cu → DPC proliferation → VEGF elevation, TGF-β1 suppression → Angiogenesis, follicle elongationPyo 2007

GHRH-R → Gαs → cAMP → PKA → GH vesicle exocytosisTeichman 2006

Downstream effect

Stimulates hair follicle elongation ex vivo, reduces dermal papilla cell apoptosis, elevates Bcl-2/Bax ratio, reduces cleaved caspase-3 and PARPPyo 2007

Pulsatile GH release matching physiological pattern; subsequent IGF-1 elevationIonescu 2006

Feedback intact?

—

Yes — short pulse preserves somatostatin negative feedbackIonescu 2006

Origin

Synthetic tripeptide with Cu²⁺ chelation — alanine substitution variant of GHK-Cu

Modified human GRF 1-29 with four substitutions (D-Ala²/Gln⁸/Ala¹⁵/Leu²⁷) for protease resistanceTeichman 2006

Antibody development

—

Not reported in short-term studies

02Dosage Protocols

Parameter

AHK-Cu

CJC-1295 (no DAC)

Effective concentration (in vitro)

10⁻¹² – 10⁻⁹ MPyo 2007

Stimulated human hair follicle elongation ex vivo and DPC proliferation in vitro.

—

Topical formulation

0.001–0.01% (estimated cosmetic range)

No standardized human protocol published — extrapolated from in vitro data.

—

Frequency

Once or twice daily (topical application)

1–2× daily (pre-sleep ± morning)

Route

Topical — scalp or dermal application

—

Evidence basis

Ex vivo hair follicle / in vitro DPC studiesPyo 2007

Phase 1 (CJC-1295 with DAC); analog dataTeichman 2006 Ionescu 2006

No-DAC variant is less studied directly; PK extrapolated from native GHRH.

Duration

Not established — cosmetic protocols typically 8–12 weeks

8–12 weeks on / 4 off (anecdotal)

Standard dose

—

100 mcg per injectionTeichman 2006

Often paired with ipamorelin in same syringe.

Lower / starter dose

—

50 mcg per dose

Reconstitution

—

Bacteriostatic water

Timing

—

Pre-sleep + fasted preferred

Half-life

—

~30 minIonescu 2006

Short pulse vs CJC-1295-DAC (~8 days). Choose no-DAC for pulsatile, DAC for sustained.

04Side Effects & Safety

Parameter

AHK-Cu

CJC-1295 (no DAC)

Local irritation

Mild erythema, pruritus at application site (copper peptide class effect)

—

Copper sensitivity

Rare hypersensitivity reaction in copper-sensitive individuals

—

Systemic absorption

Minimal via topical route — systemic copper toxicity unlikely at cosmetic doses

—

Data limitations

No published human safety trials — cosmetic use presumed safe per class precedent (GHK-Cu)

—

Injection site reaction

—

Erythema, mild pruritus

Flushing / headache

—

Common transient effect

Cortisol elevation

—

Minimal at standard doses

Prolactin elevation

—

Minimal

Glucose intolerance

—

Possible at high cumulative doses

IGF-1 elevation

—

Dose-dependent; monitor with chronic use

Cancer risk

—

Contraindicated in active malignancy (GH/IGF-1 axis)

Pregnancy / OB

—

Avoid

Absolute Contraindications

AHK-Cu

·Known copper allergy or Wilson's disease

CJC-1295 (no DAC)

·Active malignancy or cancer history
·Pregnancy / breastfeeding
·Disrupted hypothalamic-pituitary axis

Relative Contraindications

AHK-Cu

·Broken or inflamed skin (increased absorption risk)
·Concurrent use of other copper-containing formulations

CJC-1295 (no DAC)

·Untreated diabetes
·Severe insulin resistance

05Administration Protocol

Parameter

AHK-Cu

CJC-1295 (no DAC)

1. Topical application

Apply to clean, dry scalp or target dermal area. Typical cosmetic formulations: 0.001–0.01% AHK-Cu in serum or cream base.

Add 2 mL bacteriostatic water to 2 mg vial → 1 mg/mL = 100 mcg per 0.1 mL. Roll gently.

2. Frequency

Once or twice daily. Evening application preferred for overnight contact time.

Subcutaneous, abdomen or thigh. Rotate sites.

3. Scalp preparation

For hair growth: apply directly to scalp, massage gently. No need to rinse. Allow absorption for minimum 2–4 hours.

Pre-sleep preferred. Often combined with ipamorelin in the same syringe.

4. Storage

Room temperature, protected from light. Copper complexes may degrade in UV exposure.

Lyophilised: room temp, protected from light. Reconstituted: refrigerate 2–8 °C, use within 30 days.

5. Duration

Minimum 8–12 weeks to assess efficacy in hair growth applications, per typical cosmetic peptide protocols.

29–31G, 4–8 mm insulin syringe.

06Stack Synergy

AHK-Cu

+ GHK-Cu

Moderate

View GHK-Cu →

Both tripeptide-copper complexes share overlapping angiogenic and wound-healing mechanisms (VEGF elevation, TGF-β modulation, fibroblast proliferation). AHK-Cu's alanine substitution may offer distinct receptor affinity or pharmacokinetics. Co-formulation could provide complementary dermal signaling, though no direct synergy studies exist. Often used interchangeably or in alternating protocols.

AHK-Cu: 0.001–0.01% topical · AM
GHK-Cu: 0.001–0.01% topical · PM
Frequency: Daily alternation or combined formulation
Primary benefit: Comprehensive dermal regeneration, angiogenesis, hair follicle support

CJC-1295 (no DAC)

+ Ipamorelin

Strong

View Ipamorelin →

CJC-1295 (no DAC) and ipamorelin are the canonical "GHRH + GHRP" dual-axis stack at physiological timing. Both peak within 30 min and clear within 2 hours, producing a sharp, high-amplitude GH pulse closely resembling natural physiology. Preferred over the CJC-1295-DAC + ipamorelin stack when pulsatility (vs sustained elevation) is the goal.

CJC-1295 (no DAC): 100 mcg SQ · pre-sleep
Ipamorelin: 200–300 mcg SQ · same injection
Primary benefit: Pulsatile GH stimulation, recovery, body composition

Teichman 2006 Raun 1998